Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D09SBU
|
||||
Former ID |
DNC009722
|
||||
Drug Name |
C[L-Ala-D-pro-L-Phe-D-trp]
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C28H31N5O4
|
||||
Canonical SMILES |
CC1C(=O)N2CCCC2C(=O)NC(C(=O)NC(C(=O)N1)CC3=CNC4=CC=CC=C<br />43)CC5=CC=CC=C5
|
||||
InChI |
1S/C28H31N5O4/c1-17-28(37)33-13-7-12-24(33)27(36)32-22(14-18-8-3-2-4-9-18)26(35)31-23(25(34)30-17)15-19-16-29-21-11-6-5-10-20(19)21/h2-6,8-11,16-17,22-24,29H,7,12-15H2,1H3,(H,30,34)(H,31,35)(H,32,36)/t17-,22-,23+,24+/m0/s1
|
||||
InChIKey |
OTUDCPUMJPNZRR-UYGLSEIWSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Kappa-type opioid receptor | Target Info | Inhibitor | [1] | |
Mu-type opioid receptor | Target Info | Inhibitor | [1] | ||
KEGG Pathway | Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction | ||||
Estrogen signaling pathway | |||||
Morphine addiction | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Opioid prodynorphin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
Enkephalin release | |||||
Pathway Interaction Database | IL4-mediated signaling events | ||||
Reactome | Peptide ligand-binding receptors | ||||
G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
G alpha (i) signalling events | |||||
WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
Peptide GPCRs | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP69:TCR Signaling Pathway | |||||
Opioid Signalling | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. Epub 2009 May 3.Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.